56296-18-5
基本信息
DREADD Agonist 21
11-Piperazinyldibenzo[b,e][1,4]diazepine
11-(1-Piperazinyl)-5H-dibenzo[b,e][1,4]diazepine
5H-Dibenzo[b,e][1,4]diazepine, 11-(1-piperazinyl)-
物理化学性质
| 沸点 | 470.1±55.0 °C(Predicted) |
| 密度 | 1.28±0.1 g/cm3(Predicted) |
| 储存条件 | -20°C储存 |
| 溶解度 | DMSO:PBS (pH 7.2) (1:1):0.5(Max Conc. mg/mL);1.8(Max Conc. mM) Ethanol:29.61(Max Conc. mg/mL);106.39(Max Conc. mM) |
| 酸度系数(pKa) | 8.56±0.10(Predicted) |
| 形态 | 结晶固体 |
| 颜色 | 黄色 |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H315-H319-H335 |
| 防范说明 | P261-P280-P301+P312-P302+P352-P305+P351+P338 |
DREADD AGONIST 21价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/11/08 | HY-100234 | DREADD AGONIST 21 DREADD agonist 21 | 56296-18-5 | 2mg | 600元 |
| 2024/11/08 | HY-100234 | DREADD AGONIST 21 DREADD agonist 21 | 56296-18-5 | 10mM * 1mLin DMSO | 920元 |
| 2024/11/08 | HY-100234 | DREADD AGONIST 21 DREADD agonist 21 | 56296-18-5 | 5mg | 1100元 |
常见问题列表
| Target | Value |
|
hM3Dq
(Cell-free assay) | 1.7 nM(EC50) |
DREADD agonist 21 is a potent human muscarinic acetylcholine M3 receptors (hM3Dq) agonist (EC
50
=1.7 nM) and does not activate human M3 receptor (hM3). In addition to being inactive at hM3, DREADD agonist 21, a potent full agonist of hM3Dq (EC
50
=1.7 nM), is only 3.5-fold selective for hM3Dq over H1, 40-fold selective over 5HT2A, 100-fold selective over 5HT2C, and 165-fold selective over α1A. DREADD agonist 21 shows high binding affinities to 5HT2A and 5HT2C serotonin receptor, α1A adrenergic receptor, and H1 histamine receptor with K
i
values of 66, 170, 280, and 6 nM, respectively.
DREADD agonist 21 potently activates hM1Dq, hM3Dq, and hM4Di. DREADD agonist 21 binds to hM1, hM4, hM1Dq and hM4Di receptors with pK
i
s of 5.97, 5.44, 7.20, and 6.75, respectively. DREADD agonist 21 potently activates hM3Dq in Chinese hamster ovary (CHO) cells transfected cells in vitro with a pEC
50
of 8.48±0.05. DREADD agonist 21 is a highly selective and potent agonist for muscarinic DREADDs (pEC
50
for hM1Dq=6.54 and that for hM4Di=7.77 in pERK assays).
DREADD agonist 21 (0.3, 1.0, and 3.0 mg/kg; i.p.) activates neuronal hM3Dq in mice.
DREADD agonist 21 has excellent bioavailability, pharmacokinetic properties, and brain penetrability. DREADD agonist 21 (0.1, 1, and 10 mg/kg; i.p.) displays 95.1% plasma protein binding and 95% brain protein bounding in mice.